Cardiovascular Pharmacotherapeutics, 3rd Edition

Editors: William H. Frishman; and Domenic A. Sica

Product Details:
Published May 2011
ISBN: 9780979016431
Trim Size: 8.5 X11 inches
800 pages
Format: Hardcover; eBook

VIEW INSIDE

Everything practicing physicians and pharmacists need to know about drug therapy for cardiovascular disease.

A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states.

This new third edition presents an in-depth discussion of:

• All cardiovascular agents currently available

• The scientific basis behind every pharmacotherapy advance

• Mechanisms of action of cardiovascular pharmacotherapeutics

• The latest advances in cardiovascular drug therapy

• Specific drug treatments, and information on recently approved drugs

• Molecular biological advances

• Drugs in development

• Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention of disease

Also included are 8 appendices that provide practical, hands-on information on using drugs in clinical settings, including relevant pharmacokinetic information, and practical drug prescribing information.

Contents:

This edition is organized into 4 main sections.

1. The introductory section includes chapters related to relevant clinical pharmacology, the placebo effect in cardiovascular disease treatments, patient adherence to pharmacotherapy, and pharmacoeconomics.

2. The available cardiovascular drugs are reviewed, and each class of drugs is organized into separate chapters. In these chapters the reader will find detailed discussions on how to use individual drugs for prevention and treatment. New drugs in development for each class of agents are also reviewed. Compared to the first 2 editions, the editors have provided hundreds of updated reference citations, as well as adding new chapters on drugs for pulmonary hypertension, vasopressin and vasopressin antagonists, and drug-eluting stents. Since cardiovascular clinicians do not practice in a vacuum, there are also chapters in this section that deal with the pharmacotherapy of obesity, diabetes mellitus, and smoking cessation as it relates to the cardiac patient.

3. Special topics related to cardiovascular pharmacotherapy that the clinician will often encounter and includes chapters on alternative and complementary medicine, cardiovascular drug-drug interactions, pediatric cardiovascular pharmacology, antibiotic prophylaxis and treatment guidelines for endocarditis and rheumatic fever, and drug therapy of cerebrovascular and peripheral vascular diseases. The section concludes with a chapter on cytokines and myocardial regeneration as a new therapeutic option for cardiac disease and a final chapter that summarizes the status of more than 200 agents that are currently in clinical trials as innovative treatments for cardiovascular disease.

4. 8-part appendix provides practical, hands-on information on using drugs in clinical settings.    

   • Provides relevant pharmacokinetic information regarding all the available cardiovascular drugs.

   • Offers practical drug prescribing information.

   • Guides for using cardiovascular drugs in specific patient populations.

      

Note that bibliographic references are not listed in the book but are available below in the form of downloadable PDFs:

• Cardiovascular Pharmacotherapeutics, 3rd Edition references

• Cardiovascular Pharmacotherapeutics: Abridged and Updated references

Table of Contents:

Part 1: Introduction
1. Basic Principles of Clinical Pharmacology Relevant to Cardiology
William H. Frishman

2. The Placebo Effect in the Treatment of Cardiovascular Disease
William H. Frishman and Stephen P. Glasser

3. Importance of Medication Adherence in Cardiovascular Disease Treatment
William H. Frishman and Renée J. G. Arnold

4. Health Economic Considerations in Cardiovascular Drug Utilization
Renée J. G. Arnold and William H. Frishman

Part 2: Drug Classes
5. Alpha- and Beta-Adrenergic Blocking Drugs
William H. Frishman

6. Central and Peripheral Sympatholytics
Lawrence R. Krakoff and William H. Frishman

7. Cholinergic and Anticholinergic Drugs
B. Robert Meyer and William H. Frishman

8. Calcium Channel Blockers
William H. Frishman and Domenic A. Sica

9. The Renin Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

10. The Renin Angiotensin Axis: Direct Renin Inhibition
William H. Frishman and Domenic A. Sica

11. Diuretic Therapy in Cardiovascular Disease
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

12. Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies
Domenic A. Sica and William H. Frishman

13. Inotropic Agents
Thierry H. LeJemtel, Marc Klapholz, and William H. Frishman

14. The Organic Nitrates and Nitroprusside
Jonathan Abrams and William H. Frishman

15. Ranolazine: A Piperazine Derivative
William H. Frishman, James J. Nawarskas, and Joe R. Anderson

16. Nonspecific Antihypertensive Vasodilators
Lawrence R. Krakoff and William H. Frishman

17. Antiarrhythmic Drugs
Peter Zimetbaum, Peter R. Kowey, and Eric L. Michelson

18. Antiplatelet and Other Antithrombotic Drugs
William H. Frishman, Robert G. Lerner, and Harit Desai

19. Thrombolytic Agents
Robert Forman and William H. Frishman

20. Lipid-Lowering Drugs
William H. Frishman and Wilbert S. Aronow

21. New Aspects of Combination Therapy: Focus on Hypertension
Michael A. Weber

22. Pharmacotherapy for Smoking Cessation
William H. Frishman

23. Pharmacotherapy of Obesity
William H. Frishman, Harriette R. Mogul, and Stephen J. Peterson

24. Heart Disease and Treatment of Diabetes Mellitus
Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz, and William H. Frishman

25. Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension
Warren D. Rosenblum and William H. Frishman

26. Selective and Non-selective Dopamine Receptor Agonists
William H. Frishman and Chandrasekar Palaniswamy

27. Natriuretic Peptides: Nesiritide
William H. Frishman and Domenic A. Sica

28. Vasopressin and Vasopressin Receptor Antagonists
William H. Frishman, Marc Klapholz, Gerard Oghlakian, and Jacqueline M. Cook

29. Drug-Eluting Stents
James J. Nawarskas and Mark J. Ricciardi

Part 3: Special Topics
30. Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease
William H. Frishman

31. Cardiovascular Drug–Drug Interactions
Angela Cheng-Lai, James J. Nawarskas, and William H. Frishman

32. Pediatric Cardiovascular Pharmacology
Michael Gewitz, Paul Woolf, and William H. Frishman

33. Drug Therapy of Neurovascular Disease
Jesse Weinberger, William H. Frishman, and Harit Desai

34. Drug Treatment of Peripheral Vascular Disorders
Veerendra Chadachan and Robert T. Eberhardt

35. Drug Treatment and Prevention of Infective Endocarditis and Rheumatic Fever
Michael Gewitz and William H. Frishman

36. Cytokines and Myocardial Regeneration: A Novel Therapeutic Option for Acute Myocardial Infarction
William H. Frishman, Guruprasad Srinivas, and Piero Anversa

37. Cardiovascular Drugs in Development
William H. Frishman and Kalyana Pallerla

Part 4: Appendices
Angela Cheng-Lai and William H. Frishman

1. Pharmacokinetic Properties of Approved Cardiovascular Drugs
2. Therapeutic Use of Available Cardiovascular Drugs
3. Guide to Cardiovascular Drug Use in Pregnancy and with Nursing
4. Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or
Congestive Heart Failure
5. Dose Adjustment in Patients with Renal Insufficiency
6. Selected Cardiovascular Medications and Gender Issues
7. Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected
Cardiovascular Drugs in the Elderly
8. Selected Cardiovascular Medications and Ethnic Issues

Index

Doody's Review Service 4-Star Rating:

Reviewer
Mario  Pascual,  MD(Ochsner Clinic Foundation)

Description
This is a comprehensive source of information on the medications used for the prevention and treatment of cardiovascular disease.

Purpose
It provides updated information on the use of drug therapy in cardiovascular medicine.

Audience
It is intended for physicians and pharmacists involved in providing cardiovascular care to patients as well for as readers with an interest in cardiovascular pharmacology.

Features
Each chapter is divided into sections that describe the mechanism of action, the pharmacology and pharmacokinetics, and the appropriate use of each drug in cardiovascular medicine. This subdivision provides a consistent pattern that makes the book easy to use. The book offers information on medications that are currently the standard of care, new drugs in development, and alternative and complementary medications. The appendix then adds a useful resource for practical prescribing practices and drugs used in specific patient populations.

Assessment
This book provides a detailed assessment of the molecular biology, pharmacokinetics, and use of drug therapy in patients with cardiovascular disease. It not only provides clinical information about today's drugs, it also comments on therapeutic drugs that will revolutionize the practice of cardiovascular medicine in the future.